ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES THE ASPIRATIONAL AND PRACTICAL ELEMENTS OF GENERATING REAL-WORLD EVIDENCE

Published Nov 2, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted an issue panel this afternoon entitled, Real World Evidence to Support Value Proposition and Reimbursement at Launch: The Aspirational Meets the Impractical?, at the Society’s 19th Annual European Congress in Vienna, Austria. The issue panel was moderated by Kari Edwards, PhD, Managing Partner, Harbinger Health, LLC, Los Angeles, CA, USA. Panelists for the session included:
  • Adrian R. Levy, PhD, Professor and Head, Community Health and Epidemiology, Dalhousie University, Nova Scotia, AL, Canada
  • Arie Barlev, PharmD, MS, Senior Director, Health Economics and Outcomes Research, Medivation, Inc., San Francisco, CA, USA
  • Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK
The panelists explored the tension that exists between the aspirational and practical elements of generating real-world evidence in a timely fashion to support reimbursement for the launch of a new product launch. Kari Edwards, PhD presented a number of illustrative case studies to provide context and moderated the debate. Adrian R. Levy, PhD provided a payer perspective, arguing in favor of real-world evidence and noting that timely assessment of likely effectiveness would support reimbursement submissions upon product launch. Arie Barlev, PharmD, MS presented an industry view noting the practical challenges associated with collecting evidence within a short, post-approval timeframe, and highlighted the problem of selection bias when measuring relative effect in populations exposed to newly approved agents compared with standards of care. The final speaker, Andrew Briggs, DPhil, represented the health economics point of view and demonstrated the use of modeling techniques to exploit the rigorous nature of clinical trial data. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.

ISPOR Launches “HEOR Explained” Microsite

Dec 10, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has launched a new microsite—HEOR Explained—designed to help people better understand how health economics and outcomes research (HEOR) can improve healthcare decisions.

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×